A retrospective cohort study revealed the risk of long-term TKI-associated vascular adverse events for patients receiving nilotinib or dasatinib for CML, particularly as a first-line treatment.
A retrospective analysis of data identified predictors of cardiac adverse events in patients with CML undergoing treatment with tyrosine kinase inhibitors.
Researchers sought to determine the accuracy of established cardiovascular assessment tools in predicting risk of CV events in patients with CML receiving TKIs.
Clinical trial focusing on the molecular epidemiology of childhood leukemia. Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study) (CCLS)
Clinical trial focusing on carfilzomib Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL). Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
.
